drugset / Trial / NCT05687526
A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-center, open-label, phase 1 study.
Timeline
- Start
- 2023-05-25
- Primary completion
- 2025-11-14
- Completion
- 2025-11-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telitacicept | Protein / enzyme biologic | 2.5 mg/kg | Subcutaneous |
| Subject | Telitacicept | Protein / enzyme biologic | 3 mg/kg | Subcutaneous |
| Subject | Telitacicept | Protein / enzyme biologic | 3.5 mg/kg | Subcutaneous |